Comparative in vitro activity of quinolones against Stenotrophomonas maltophilia. 1999

S Valdezate, and A Vindel, and F Baquero, and R Cantón
Servicio de Microbiología, Hospital Ramón y Cajal, Madrid, Spain.

The susceptibility of 109 Stenotrophomonas maltophilia isolates, all characterized by pulsed-field gel electrophoresis, to nine quinolones was studied. Grepafloxacin, trovafloxacin, and moxifloxacin displayed similar intrinsic activities (MIC90, 0.5 microg/ml), which were lower than those of ofloxacin and ciprofloxacin (MIC90, 4 microg/ml), norfloxacin (MIC90, 64 microg/ml), and nalidixic acid (MIC90, 32 microg/ml). Nalidixic acid was generally one- to twofold dilutions more active than norfloxacin. According to the criteria of the National Committee for Clinical Laboratory Standards (NCCLS), the percentage of isolates susceptible to ciprofloxacin (breakpoint < or = 1 microg/ml) was 76.1%. Using the NCCLS breakpoint for comparative purposes, the percentage of isolates susceptible to grepafloxacin, moxifloxacin, and trovafloxacin was 95.4, 96.4, and 96.4%, respectively. These results indicate that new quinolones may potentially be used for the management of Stenotrophomonas maltophilia infections.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D016905 Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method. Bacterial Infections, Gram-Negative,Infections, Gram-Negative Bacterial,Bacterial Infection, Gram-Negative,Gram Negative Bacterial Infections,Gram-Negative Bacterial Infection,Infection, Gram-Negative Bacterial
D042462 4-Quinolones QUINOLONES containing a 4-oxo (a carbonyl in the para position to the nitrogen). They inhibit the A subunit of DNA GYRASE and are used as antimicrobials. Second generation 4-quinolones are also substituted with a 1-piperazinyl group at the 7-position and a fluorine at the 6-position. 4-Oxoquinoline,4-Quinolinone,4-Quinolone,4-Oxoquinolines,4-Quinolinones,4 Oxoquinoline,4 Oxoquinolines,4 Quinolinone,4 Quinolinones,4 Quinolone,4 Quinolones
D020615 Stenotrophomonas maltophilia A species of STENOTROPHOMONAS, formerly called Xanthomonas maltophilia, which reduces nitrate. It is a cause of hospital-acquired ocular and lung infections, especially in those patients with cystic fibrosis and those who are immunosuppressed. Xanthomonas maltophilia,Pseudomonas maltophilia

Related Publications

S Valdezate, and A Vindel, and F Baquero, and R Cantón
March 2000, The Journal of antimicrobial chemotherapy,
S Valdezate, and A Vindel, and F Baquero, and R Cantón
December 2014, Journal of global antimicrobial resistance,
S Valdezate, and A Vindel, and F Baquero, and R Cantón
August 2000, The Journal of antimicrobial chemotherapy,
S Valdezate, and A Vindel, and F Baquero, and R Cantón
September 1999, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia,
S Valdezate, and A Vindel, and F Baquero, and R Cantón
April 2005, Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti J.E. Purkyne,
S Valdezate, and A Vindel, and F Baquero, and R Cantón
March 2021, Antimicrobial agents and chemotherapy,
S Valdezate, and A Vindel, and F Baquero, and R Cantón
July 2010, Diagnostic microbiology and infectious disease,
S Valdezate, and A Vindel, and F Baquero, and R Cantón
February 2002, Diagnostic microbiology and infectious disease,
S Valdezate, and A Vindel, and F Baquero, and R Cantón
July 2005, Antimicrobial agents and chemotherapy,
S Valdezate, and A Vindel, and F Baquero, and R Cantón
October 1995, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!